1. Home
  2. Research
  3. Research Groups
  4. Surgical research in urology and renal trasplantation

Surgical research in urology and renal trasplantation

Search for publications

Only original articles, editorials, guidelines.

  • Contieri R, de Angelis M, Scilipoti P, Pellegrino F, Longoni M, Afferi L, Zamboni S, Suardi N, Subiela JD, Musi G, Di Trapani E, Mistretta FA, D'Andrea D, Laukhtina E, Soria F, Gontero P, Del Giudice F, Beatrici E, De Groote R, Mottrie A, Rouprêt M, Grobet-Jeandin E, Baudewyns A, Tanaka H, Proietti F, Simone G, Schulz GB, Pyrgidis N, Ploussard G, Antonelli A, Bertolo R, Roumiguié M, Bajeot AS, Mir MC, Umari P, Teoh JYC, Pichler R, Mori K, Slusarczyk A, Poyet C, Albisinni S, Aziz A, Shariat SF, Minervini A, Mari A, Lambertini L, Aveta A, Spena G, Izzo A, Montorsi F, Briganti A, Pradere B, van Rhijn BWG, Hurle R, Claps F, Perdonà S, PeMoschinirdonà M, Mertens LS.

    When, where, and in whom does recurrence occur after radical cystectomy for pathologically confirmed non-muscle-invasive bladder cancer? Implications for risk-adapted surveillance.

    WORLD JOURNAL OF UROLOGY . 44(1): .

    [doi:10.1007/s00345-026-06850-y]

  • Fernández-Conejo G, González Álvarez C, Del Olmo Durán P, Tagalos Muñoz A, Sanz Mayayo E, Diez Nicolás V, García Barreras S, Subiela Henríquez JD, Rodríguez-Patrón R, Pérez-Fernández E, Gómez Dos Santos V, Burgos Revilla FJ.

    Learning curve of Versius-assisted radical prostatectomy: role of prior experience and proctoring.

    BJU INTERNATIONAL . 138(5): 905-914. Number of citations: 1

    [doi:10.1111/bju.70405]

  • Subiela JD, Gomis Sellés E, López Campos F, Aumatell J, González-Padilla DA, Balbás ÁG, López-Curtis D, Vera Barragán V, Caño-Velasco J, Picola Brau N, de Pablos-Rodríguez P, Gómez Rivas J, San-José Manso L, Burgos Revilla FJ, Barletta F, Alongi F, Zamboglou C, Nicosia L, Shelan M, Conde-Moreno AJ, Gajate P, Guerrero P, Buisan Ò, Couñago F.

    Whole-pelvic Versus Prostate-only Radiotherapy in Clinically Node-negative High-Risk Localised Prostate Cancer: A Systematic Review and Meta-analysis with Reconstructed Individual-patient Data.

    CLINICAL ONCOLOGY . 59: 104329-104329.

    [doi:10.1016/j.clon.2026.104329]

  • Ugalde B, Juez LD, Ruiz-Torres I, Perea-Fuentes I, Martos S, DeVicente I, Melero D, Blázquez J, Botella-Carretero JI.

    Immunonutrition vs. Standard Oral Nutritional Supplements in Prehabilitation for Colorectal Cancer Surgery: A Randomized Clinical Trial Assessing Morbidity and Body Composition by Computed Tomography.

    Nutrients . 18(20): .

    [doi:10.3390/nu18203381]

  • Rini BI, Powles T, Tomczak P, Shin SJ, Guo J, Molina-Cerrillo J, Ren X, Lee JL, Wysocki PJ, Puente J, Basu A, Mar N, Bernhard S, Khan O, Ha J, Colley L, Prizant H, Albiges L.

    A randomised, open-label, phase II study of tobemstomig combinations in patients with previously untreated advanced clear-cell renal cell carcinoma.

    ESMO Open . 11(10): 108587-108587.

    [doi:10.1016/j.esmoop.2026.108587]

  • Urun Y, Sridharan K, Zgura A, Zayed A, Laguado MIZ, Yetisyigit T, Yano A, Wenzel M, Vau N, Tural D, Trindade K, Tran B, Ting FIL, Templeton AJ, Takeshita H, Sunela K, Souza VC, Sooro MA, Soares A, Siva S, Singh A, Silveira G, Shah S, Seront E, Schutz FA, Schurmann MLV, Schieber T, Scagliarini S, Sargsyan A, Simonetti CS, Rushanyan M, Roviello G, Rodriguez-Vida A, Rodriguez Gonzalez OE, Roberts R, Van der Veldt AAM, Rizzo M, Rizzo A, Poprach A, Pirshtuk A, Pinto A, Pierce E, Peñaloza JM, Pedrani M, Park SH, Okunade IA, Odounga KF, Noriega J, Noorzai E, Coronel MTN, Navratil J, Myint ZW, Mutavdzic V, Mukuku O, Mugarura R, Marques Monteiro FS, Mohamed AH, Mmereki D, Messina C, Melichar B, Mukaz Mbey P, Maturana E, Matthews D, Massari F, Martínez E, Maitre P, Maison P, Ndjembidouma BCM, Lu K, Li J, Li H, de Moura Leite L, Lalani AA, Küronya Z, Kucharz J, Koumba AB, Kopp RM, Kopecky J, Kihn-Alarcón AJ, Keskin Ö, Kabdullina K, Juarez Á, Fita MJJ, Jardim DL, James LG, Grande E, De Liaño AG, Giannatempo P, Ghosn M, Gauna C, Quiroga MNG, Fujita K, Pereira Freitas MR, Fiala O, Lazzaro MF, Pacheco GMF, Esan TO, Esan DT, Du Plessis D, Delgado SN, Crabb SJ, Cano RC, Corrales L, Chen J, Cayol F, Silva CC, Carneiro APCD, Caprinciu GA, Campos S, Büttner T, Buti S, Bukhari N, Buchler T, Bourlon MT, Bolek H, Boegemann M, Bilen MA, Vaca LB, Bastos DA, Barthelemy P, Bardakhchyan S, Barbu MA, Baranseh J, Bamias A, Bakenga A, Anguera G, Angel M, Silva CAC, Alonso-Gordoa T, Almugbel F, Almufti R, Almeida TL, Aliyev A, Aliaga C, Aleem U, Akkus E, Aceituno LG, Abidi SH, Abahssain H, Tartari F, Molina-Cerrillo J, Santoni M.

    Global disparities in the availability and reimbursement of systemic therapies for renal cell carcinoma: results of the International ARON-AID Survey.

    ONCOLOGIST . 31(11): .

    [doi:10.1093/oncolo/oyag397]

  • Velasco G, Alonso-Gordoa T, Rodríguez-Moreno JF, Duran I, Carril Ajuria L, Álvarez Ballesteros P, González-Billalabeitia E, Domínguez JI, García-Casas A, Pérez-Navarro E, Sánchez-Redondo S, Molina-Cerrillo J, Guerrero-Ramos F, Manneh Kopp R, Marinas C, Paramio JM, Peinado H, Castellano D, Dueñas M.

    CABOPRE: Evaluating Perioperative Cabozantinib's Efficacy and Biomarkers for Cytoreductive Nephrectomy in Advanced Renal Cell Carcinoma.

    Cancers . 18(19): .

    [doi:10.3390/cancers18193216]

  • Garcia-Carbonero R, Cote GM, Le Cesne A, Antón-Pascual B, Alonso-Gordoa T, Falcon A, Gil-Torralvo A, Martínez S, Kahatt C, Alfaro V, Zubiaur P, Jimenez J, Siguero M, Molina-Cerrillo J.

    Lurbinectedin plus irinotecan in pretreated gastroenteropancreatic neuroendocrine neoplasms: results of a phase II expansion cohort.

    ESMO Open . 11(10): 108534-108534.

    [doi:10.1016/j.esmoop.2026.108534]

  • Sridharan K, Fiala O, Sivaramakrishnan G, Matrana MR, Büttner T, Kucharz J, Molina Cerrillo J, Giannatempo P, Myint ZW, Gómez de Liaño A, Pirshtuk A, Mota A, Kanesvaran R, Ürün Y, Angel M, Soule T, Massari F, Bellmunt J, Gupta S, Santoni M.

    Machine learning-integrated explainable artificial intelligence for survival prediction in urothelial carcinoma with enfortumab vedotin: an exploratory real-world analysis.

    EXPERT OPINION ON BIOLOGICAL THERAPY . 26(10): 1-11.

    [doi:10.1080/14712598.2026.2727098]

  • Scilipoti P, Slusarczyk A, Subiela JD, Longoni M, Occhi A, Zaurito P, Tremolada G, Maiorano B, Soria F, Krajewski W, D'Andrea D, Claps F, Del Giudice F, Pichler R, Grobet-Jeandin E, Gallioli A, Afferi L, Mastroianni R, Simone G, Mertens LS, Laukhtina E, Rodriguez Elena JL, Aranda J, Lafuente Puentedura A, Caño Velasco J, Contieri R, Zorzi F, Liguori G, Hurle R, Cirulli GO, Naspro R, Mori K, Marcq G, Radziszewski P, Shariat SF, Gontero P, Rouprêt M, Seisen T, Montorsi F, Briganti A, Pradere B, Moschini M.

    Surrogacy of intermediate clinical endpoints for overall survival in BCG-naïve high-risk non-muscle-invasive bladder cancer.

    WORLD JOURNAL OF UROLOGY . 44(1): .

    [doi:10.1007/s00345-026-06840-0]

  • Caño-Velasco J, Luis-Cardo A, Moreno-Cortés JC, Carrasco-Loras L, Astudillo-Campoverde J, Subiela JD, Lozano-Palacio F, Campistol-Torres M, Pichler R, Partl A, Lackner F, Giudice FD, Carino D, García-Martín LA, Salamanca-Blanco P, Bielsa-Carrillo A, Pastor-Cordero AM, Bataller-Monfort V, Tello-Delsors A, Polanco-Pujol L, Lafuente-Puentedura A, Aragón-Chamizo J, Herranz-Amo F, Barbas-Bernardos G, González-Padilla DA, Villacampa-Aubá F, Sánchez-Zalabardo D, Robles-García JE, Miñana-López B, Moschini M, Soria F, D'Andrea D, Mertens LS, Teoh JYC, Albisinni S, Pradere B, Hernández-Fernández C.

    Impact of intravesical BCG Therapy on quality of life in non-muscle-invasive bladder cancer: a prospective evaluation using the FACT-Bl questionnaire.

    Actas Urologicas Espanolas . 50(8): 501937-501937.

    [doi:10.1016/j.acuroe.2026.501937]

  • Willisch P, Vázquez-Barreiro B, Plata A, Belmonte IC, Guardia G, Del Castillo-Acuña R, Francolini G, Franzese C, Henríquez JDS, Couñago F, López-Campos F.

    Androgen receptor pathway inhibitor intensification in non-metastatic hormone-sensitive prostate cancer: current evidence and clinical implications.

    Clinical & Translational Oncology . 28(10): 4376-4388.

    [doi:10.1007/s12094-026-04350-4]

  • Sridharan K, Alonso-Gordoa T, Sivaramakrishnan G, Cerrillo JM, Fiala O, Rehan F, Mena Cortes D, Santoni M.

    Theranostics in the management of prostate cancer: from concept to clinical practice.

    Expert Review of Clinical Pharmacology . 19(9): 837-854.

    [doi:10.1080/17512433.2026.2737765]

  • Jonsson G, Oliveira T, Hofmann M, Lemberger U, Stejskal K, Krššáková G, Sakic I, Novatchkova M, Mereiter S, Grabmann G, Köcher T, Koglgruber R, Kikic Z, Camano Páez S, Luna Sanchez B, Díez Nicolás V, Rechberger GN, Züllig T, Hagelkruys A, Englinger B, Schmidinger M, Penninger JM.

    Urinary multi-omics reveal non-invasive diagnostic biomarkers in clear cell renal cell carcinoma.

    EMBO Molecular Medicine . 18(9): 3649-3676.

    [doi:10.1038/s44321-026-00498-2]

  • Rizzo M, Buti S, Fiala O, Incorvaia L, Molina-Cerrillo J, Bourlon MT, Fukuokaya W, Urabe F, Park SH, Mayrhofer K, Pichler R, Niedersuess-Beke D, Taha T, Büttner T, Bamias A, Seront E, Santini D, Stumbo L, Rodriguez-Vida A, Massari F, Monteiro FSM, Soares A, Grande E, Santoni M.

    Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study).

    Targeted Oncology . 21(5): 775-784.

    [doi:10.1007/s11523-026-01238-9]

  • Büttner T, Rizzo M, Bernal Vaca L, Molina-Cerrillo J, Alonso-Gordoa T, Juárez A, Buchler T, Seront E, Kucharz J, Gandur Quiroga MN, Bourlon MT, Bögemann M, Kopecky J, Rescigno P, Fiala O, Rodriguez-Vida A, Myint ZW, Ürün Y, Scagliarini S, Poprach A, Matthews D, Li H, Rizzo A, Mosca A, Lenci E, Melichar B, Wenzel M, Mandell P, Massari F, Antonarakis ES, Santoni M.

    Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study.

    PROSTATE CANCER AND PROSTATIC DISEASES . 29(3): 588-594. Number of citations: 11

    [doi:10.1038/s41391-025-01067-3]

  • Molina-Cerrillo J, Alonso-Gordoa T.

    Re: Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer.

    EUROPEAN UROLOGY . 90(3): 304-305.

    [doi:10.1016/j.eururo.2026.04.007]

  • Valdez-Sandoval PI, Beas-Lozano EL, Myint ZW, Kucharz J, Mollica V, Rizzo A, Taha T, Landmesser J, Pérez Calabuig E, Ansari J, Ortega C, Kanesvaran R, Bhuva D, Zgura A, Fiala O, Molina-Cerrillo J, Buti S, Massari F, Esparza-Orozco MF, Santoni M, Bourlon MT.

    Sex-based analysis of first-line immune-based combinations in intermediate/poor-risk papillary, chromophobe, and unclassified renal cell carcinoma: an ARON-1 subanalysis.

    Frontiers in Oncology . 16: 1911444-1911444.

    [doi:10.3389/fonc.2026.1911444]